Literature DB >> 8305838

Mediation of immune glomerular injury.

W G Couser1.   

Abstract

Although glomerular disease remains the most common cause of end-stage renal disease worldwide, major advances have been made recently in understanding the cellular and molecular mechanisms which mediate these disorders. Nephrotic syndrome in non inflammatory lesions such as minimal-change/focal sclerosis and MN results from disorders of the GEC which can be simulated in animal models by antibodies to various GEC membrane epitopes. Clarification of how these antibodies effect the GEC to induce a loss of glomerular barrier function should substantially improve understanding of the pathogenesis of minimal change/focal sclerosis. In MN, proteinuria is mediated primarily by C5b-9 through similar mechanisms that also involve the GEC as a target. Inflammatory glomerular lesions are induced by circulating inflammatory cells or proliferating resident glomerular cells. Understanding of how these cells induce tissue injury has also evolved considerably over the past decade. Neutrophil-induced disease involves leukocyte adhesion molecules in regulating neutrophil localization; proteases, oxidants, and myeloperoxidase in mediating injury and platelets in augmenting these processes. The activated mesangial cell exhibits altered phenotype and proliferation with release of oxidants and proteases. Mesangial cell proliferation may be initiated by basic fibroblast growth factor and is maintained by an autocrine mechanism involving PDGF. TGF-beta is important in the subsequent development of sclerosis. As understanding of these areas evolves, numerous new therapeutic strategies can now be devised, including agents which block or inhibit complement effects, oxidants, proteases, growth factors, and other cytokines. Appreciation of the role of several natural inhibitors of these mechanisms may also allow therapeutic manipulations that upregulate regulatory proteins, with a consequent therapeutic benefit.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8305838     DOI: 10.1007/BF00190325

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  10 in total

Review 1.  Role of C5b-9 in experimental membranous nephropathy.

Authors:  W G Couser; M Schulze; C J Pruchno
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

Review 2.  T cells and macrophages and their role in renal injury.

Authors:  I W Main; D J Nikolic-Paterson; R C Atkins
Journal:  Semin Nephrol       Date:  1992-09       Impact factor: 5.299

Review 3.  Platelets in inflammatory glomerular injury.

Authors:  R J Johnson
Journal:  Semin Nephrol       Date:  1991-05       Impact factor: 5.299

Review 4.  The activated mesangial cell: a glomerular "myofibroblast"?

Authors:  R J Johnson; J Floege; A Yoshimura; H Iida; W G Couser; C E Alpers
Journal:  J Am Soc Nephrol       Date:  1992-04       Impact factor: 10.121

Review 5.  Mediation of immune glomerular injury.

Authors:  W G Couser
Journal:  J Am Soc Nephrol       Date:  1990-07       Impact factor: 10.121

Review 6.  Role of oxidants and proteases in glomerular injury.

Authors:  R J Johnson; D Lovett; R I Lehrer; W G Couser; S J Klebanoff
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

7.  Role of platelet-derived growth factor in glomerular disease.

Authors:  R J Johnson; J Floege; W G Couser; C E Alpers
Journal:  J Am Soc Nephrol       Date:  1993-08       Impact factor: 10.121

8.  A glomerular permeability factor produced by human T cell hybridomas.

Authors:  A Koyama; M Fujisaki; M Kobayashi; M Igarashi; M Narita
Journal:  Kidney Int       Date:  1991-09       Impact factor: 10.612

Review 9.  Mechanisms of proteinuria in noninflammatory glomerular diseases.

Authors:  V J Savin
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

Review 10.  Mesangial cells in the pathogenesis of progressive glomerular disease in animal models.

Authors:  J Floege; R J Johnson; W G Couser
Journal:  Clin Investig       Date:  1992-09
  10 in total
  1 in total

1.  Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis.

Authors:  Jukka M Rintala; Johanna Savikko; Sini E Rintala; Niina Palin; Petri K Koskinen
Journal:  J Nephrol       Date:  2015-09-30       Impact factor: 3.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.